Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer

Scroll down to access downloads and media.

Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers

Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers [PDF - 176 KB] - 3 pages

Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers [Word - 119 KB] - 3 pages

About this resource

Publication date:

23 January 2023

Publication type:

Procedure

Audience:

General public

Language:

English

Part of a collection:

Life Saving Drugs Program resources – Fabry disease

Tags:

Sub menu

Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers

Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers

About this resource

Help us improve health.gov.au